Drugs for bad bugs: confronting the challenges of antibacterial discovery
about
A brief history of the antibiotic era: lessons learned and challenges for the futureWhen the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transitionNew approaches to filling the gap in tuberculosis drug discoveryPurification and characterization of a novel lipopeptide from Streptomyces amritsarensis sp. nov. active against methicillin-resistant Staphylococcus aureusWhen Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility CrisisPrivileged scaffolds for library design and drug discoveryUse of ichip for high-throughput in situ cultivation of "uncultivable" microbial speciesA vast collection of microbial genes that are toxic to bacteriaStrategies to minimize antibiotic resistanceBiosynthesis and functions of mycothiol, the unique protective thiol of ActinobacteriaBiotin Protein Ligase Is a Target for New AntibacterialsA systematic review and critical assessment of incentive strategies for discovery and development of novel antibioticsAntibacterial Discovery and Development: From Gene to Product and BackThe application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosisWhole-genome sequencing targets drug-resistant bacterial infectionsNext-generation antimicrobials: from chemical biology to first-in-class drugsAlternative strategies for proof-of-principle studies of antibacterial agentsMycobacterium tuberculosis: success through dormancyTuberculosis drug discovery in the post-post-genomic eraRecent developments in drug discovery for leishmaniasis and human African trypanosomiasisColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyAntimicrobial resistance in Acinetobacter baumannii: From bench to bedsideAn image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophagesLearning from the past for TB drug discovery in the futureThe Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesStructural genomics and drug discovery for infectious diseasesEssential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosisIncreasing the structural coverage of tuberculosis drug targetsBisphosphonates target multiple sites in both cis- and trans-prenyltransferasesComprehensive Mechanistic Analysis of Hits from High-Throughput and Docking Screens against β-LactamaseA class of selective antibacterials derived from a protein kinase inhibitor pharmacophoreMolecular docking and ligand specificity in fragment-based inhibitor discoveryStructural Studies of Pterin-Based Inhibitors of Dihydropteroate SynthaseComplexes of Bacterial Nicotinate Mononucleotide Adenylyltransferase with Inhibitors: Implication for Structure-Based Drug Design and ImprovementStructural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistanceRegioselective deacetylation based on teicoplanin-complexed Orf2* crystal structuresApplying Molecular Dynamics Simulations to Identify Rarely Sampled Ligand-bound Conformational States of Undecaprenyl Pyrophosphate Synthase, an Antibacterial TargetLeveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomalleiInterception of teicoplanin oxidation intermediates yields new antimicrobial scaffoldsStructure ofFrancisella tularensispeptidyl-tRNA hydrolase
P2860
Q21131155-2F76F088-5DC7-4BEE-A7B1-1F21CFAE86F0Q21145725-291C045F-84F7-4324-B6B8-BF62930C1BE7Q21563416-836A3F97-44C8-4851-9ED5-48905C8CC3A7Q21999339-810257C4-586D-412B-B11B-832304E51BE4Q24288687-091BF20B-DDCD-4D5E-BBE4-DDDCFFF4AD99Q24604575-435E80D2-FBA8-4504-83F8-203ECD7F0239Q24605448-8762705D-9907-438E-BC00-1A57CB6ED98DQ24606728-812B0234-3F50-48C6-B27A-3A6A8D47D378Q24607946-BB1B334B-3516-40E4-B69D-E24F7FE629DEQ24646505-DD1422C1-2176-4E79-9167-1FDDA95562A2Q26741311-07198DEB-B6B8-4947-AE6E-490A3C8C4A8DQ26783545-8F4890DC-EC3F-4566-9970-06E764865463Q26784492-C88F522B-BEC1-415D-9D02-FDB61AFD7F08Q26795478-18E43135-2388-4485-BA6F-72ED20CEC6B8Q26799059-3CEB7E34-5810-410B-99EC-1A86C8E1429FQ26799749-A53642BE-804F-441E-B83F-C5A3B7312F27Q26850895-AF18F5FE-23A6-450D-9B87-09EB4463208EQ26852023-6BC054FC-9529-4203-8F92-DC9B9CC38059Q26864729-43D45C0A-3EA6-467D-9A1F-040EB7ADAA1BQ27011766-D097E807-2020-4ADB-8207-053E633D1E01Q27014993-8C70C2F2-FCFE-40F5-858C-EEE233094C31Q27024893-25A6815E-8FF5-465F-AC97-91BDB931B376Q27305418-2C75F176-58E0-48AD-B402-587367BA0638Q27485405-D50BA9F3-1159-4A36-B6AC-CC705840005EQ27489856-BBAA530E-03E9-4D60-842A-A86AD6880971Q27490495-0D766134-3160-4DC8-BF60-70DF72C97860Q27644255-D8F8CDE7-E0C7-4832-9458-BC8EEA23A945Q27644314-250D9405-2735-4A40-8586-CC17DCD7D554Q27645000-7BC21FFD-2FFC-4AC4-9246-FDF0C86D4A72Q27650049-1A092E59-E29A-4B6D-B22A-33F33873292DQ27653498-8F1CD90D-83B0-45E2-B5FA-36EA8230F972Q27654237-FB753C33-4445-4C80-8FFB-C71D28A8418AQ27658109-EA49DE43-AFB5-4218-B3DC-F69E4579F68AQ27662749-BBDAF2C9-8571-4AFB-963A-89EE0AEC566DQ27664216-5F38F234-7652-4837-AFB5-460CCADEABE6Q27666579-D593BC46-43A5-4BE0-91C3-9F8C24584429Q27666848-2F84A890-D6B8-42EC-8010-630B75029684Q27667103-DDC88A78-82C3-4925-A883-BD608E5769E3Q27667190-7A6FD6F4-F024-4087-82D4-1E64C18B6ADCQ27667581-36A97FD3-ABF1-4E83-952D-33A559296C53
P2860
Drugs for bad bugs: confronting the challenges of antibacterial discovery
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Drugs for bad bugs: confronting the challenges of antibacterial discovery
@ast
Drugs for bad bugs: confronting the challenges of antibacterial discovery
@en
type
label
Drugs for bad bugs: confronting the challenges of antibacterial discovery
@ast
Drugs for bad bugs: confronting the challenges of antibacterial discovery
@en
prefLabel
Drugs for bad bugs: confronting the challenges of antibacterial discovery
@ast
Drugs for bad bugs: confronting the challenges of antibacterial discovery
@en
P2093
P3181
P356
P1476
Drugs for bad bugs: confronting the challenges of antibacterial discovery
@en
P2093
P2888
P3181
P356
10.1038/NRD2201
P407
P577
2007-01-01T00:00:00Z
P5875
P6179
1005793977